2	associated	with
2	changes	in
2	of	inhaled
2	iNO	or
2	use	of
1	delivery	devices
1	points	using
1	hemodynamic	effects.
1	epoprostenol	(aEPO)
1	either	iNO
1	clinical	outcomes.
1	using	standard
1	on	currently
1	for	iNO
1	consistent	end
1	in	the
1	conditions	associated
1	treatment	of
1	reporting	on
1	ARDS	and
1	in	disease
1	mechanical	ventilation
1	estimated	mortality
1	of	either
1	in	patients
1	ALI	or
1	and	aerosolized
1	an	estimated
1	were	examined
1	aEPO	is
1	and	ALI.
1	were	included
1	on	changes
1	currently	available
1	devices	and
1	been	observed
1	to	use
1	observed	in
1	the	clinical
1	benefit	with
1	the	safety
1	studies	addressing
1	injury	(ALI)
1	determine	the
1	end	points
1	and	standard
1	with	an
1	ventilator-free	days,
1	examined	for
1	modes	of
1	(iNO)	and
1	vasodilators	can
1	guide	to
1	the	article
1	This	article
1	overall	benefit
1	acute	lung
1	standard	modes
1	is	safe
1	attenuation	in
1	relevant	studies
1	or	ARDS
1	(ARDS)	and
1	available	data,
1	safety	and
1	respiratory	distress
1	survival,	ventilator-free
1	oxygenation	without
1	standard	delivery
1	to	the
1	in	oxygenation.
1	(aEPO)	in
1	(ALI)	are
1	disease	severity.
1	or	aEPO.
1	of	40â€“50%.
1	the	use
1	article	also
1	have	been
1	and	efficacy
1	to	determine
1	trials	were
1	clinical	application
1	article	reviews
1	or	attenuation
1	a	practicable
1	with	consistent
1	days,	or
1	The	use
1	randomized	controlled
1	included	for
1	mortality	of
1	aerosolized	epoprostenol
1	and	acute
1	differences	have
1	in	oxygenation
1	In	addition,
1	syndrome	(ARDS)
1	data,	the
1	practicable	guide
1	patients	with
1	are	conditions
1	No	differences
1	can	help
1	studies	with
1	of	these
1	oxide	(iNO)
1	to	improve
1	application	of
1	transiently	improve
1	use	in
1	hypoxemia	associated
1	oxygenation	or
1	also	provides
1	controlled	trials
1	efficacy	of
1	lung	injury
1	the	overall
1	reports	of
1	these	therapies.
1	help	to
1	Further	studies
1	addressing	the
1	Nine	prospective
1	safe	to
1	of	aEPO
1	Seven	reports
1	distress	syndrome
1	Acute	respiratory
1	provides	a
1	Based	on
1	are	needed
1	with	ALI
1	or	clinical
1	in	survival,
1	inhaled	vasodilators
1	iNO	reporting
1	the	treatment
1	ARDS	to
1	aEPO	were
1	prospective	randomized
1	nitric	oxide
1	without	hemodynamic
1	of	mechanical
1	improve	oxygenation.
1	or	aEPO
1	of	life-threatening
1	ventilation	are
1	to	transiently
1	inhaled	nitric
1	life-threatening	hypoxemia
1	with	iNO
1	improve	oxygenation
1	for	changes
1	with	ARDS
1	needed	to
1	reviews	relevant
1	addition,	the
